Zevalin

Zevalin (ibritumomab tiuxetan) is an intravenous therapy for certain types of cancer affecting the lymphatic system. It targets CD20-positive B-cells to support treatment of relapsed or refractory non-Hodgkin lymphoma. This radioimmunotherapy is administered under medical supervision. Short version: Zevalin treats specific lymphomas via targeted radioimmunotherapy in clinical settings.

Zevalin is used in patients with relapsed or refractory non-Hodgkin lymphoma, particularly follicular B-cell types. It may be prescribed when other treatments have not been effective. The therapy targets CD20-positive B-cells to help manage cancer progression. Patients often ask, what is ibritumomab tiuxetan used for, and it is indicated for certain lymphomas after prior therapies.

After administration, Zevalin works by binding to B-cells and delivering targeted radiation. Patients may experience effects related to the underlying condition and treatment process. Common effects can include fatigue or temporary changes in blood cell counts. The therapy is designed to focus radiation on cancerous cells while sparing healthy tissue.

Zevalin requires careful handling and administration by healthcare professionals. Patients should inform their provider about all medications and medical conditions before treatment. Pregnant or breastfeeding individuals should avoid this therapy due to potential risks. Regular monitoring of blood counts and organ function is typically required during and after treatment.

Zevalin may interact with other therapies affecting the immune system or blood cell production. Patients on immunosuppressive drugs or with recent live vaccines should discuss risks with their doctor. Alcohol and certain supplements may also interact; consult a healthcare provider. Always disclose all current medications to avoid potential complications.